Skip to main content

Table 2 – Adverse events and serious adverse events relating to diabetes mellitus

From: No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study

MedDRA PT (AE/SAE)

Indication and GHD onset, pretreatment status

Body weight at baseline (kg)

HbA1c at baseline (%)

Dose at AE onseta (mg/day)

Time to AE/SAE onsetb (day)

BMI at AE onset (kg/m2)

Intensity

Causalityc

Outcome

Treatment with Omnitrope®

Relevant medical history; Concomitant medication; Cardiovascular AE (Y if reported)

Diabetes mellitus (AE)

MPHD in childhood, pretreated

125.6

6.00

0.40

398

41.9

NR

Not suspected

Ongoing

Not changed

None

Diabetes mellitus (AE)

Isolated GHD in adulthood, naïve

67.4

6.08

0.20

694

28.1

Moderate

Not suspected

Ongoing

Not changed

None

Diabetes mellitus (SAE)

MPHD in adulthood, naïve

131.0

5.00

0.40

608

42.8

Moderate

Not suspected

Ongoing

Not changed

None; Hydrocortisone, statin

Diabetes mellitus inadequate control (AE)

MPHD in adulthood, naïve

131.0

5.00

0.40

2338

46.7

NR

Not suspected

Ongoing

Not changed

None; Hydrocortisone, statin

Diabetes mellitus [verbatim; worsening of diabetes] (SAE)

MPHD in adulthood, naïve

92.9

NR

0.20

127

29.3

Mild

Suspected

Ongoing

Permanently discontinued

Diabetes mellitus

Diabetes mellitus [verbatim; worsening of diabetes] (SAE)

MPHD in adulthood, pretreated

63.6

10.11

0.10

1

25.2

Mild

Suspected

Ongoing

Interrupted

Type 2 diabetes mellitus; Hydrocortisone, statin

Diabetes mellitus inadequate control (AE)

MPHD in adulthood, naïve

107.2

6.90

0.20

168

38.0

Mild

Not suspected

Ongoing

Not changed

Type 2 diabetes mellitus; Hydrocortisone, statin

Diabetes mellitus type 2 inadequate control (AE)

MPHD in adulthood, naïve

74.3

8.92

NR

NR

NR

Moderate

Not suspected

Ongoing

Not changed

Type 2 diabetes mellitus; Hydrocortisone, statin

Type 2 diabetes mellitus (AE)

MPHD in adulthood, naïve

107.6

6.00

0.15

841

39.6

Mild

Not suspected

Ongoing

Not changed

None; Hydrocortisone, statin

Type 2 diabetes mellitus (AE)

MPHD in adulthood, pretreated

99.7

6.18

0.50

1041

33.4

Moderate

Not suspected

Ongoing

Not changed

Cushing’s syndrome; Statin; Y

Type 2 diabetes mellitus (AE)

MPHD in adulthood, pretreated

95.8

NR

0.15

1130

37.9

Mild

Not suspected

Ongoing

Not changed

None; Hydrocortisone

Type 2 diabetes mellitus (AE)

MPHD in adulthood, pretreated

123.9

6.70

0.50

372

51.6

Mild

Not suspected

Ongoing

Not changed

Diabetes mellitus; Cushing’s syndrome; hydrocortisone

Type 2 diabetes mellitus (AE)

MPHD in adulthood, naïve

90.0

6.30

0.20

360

37.5

Mild

Not suspected

Ongoing

Not changed

Type 2 diabetes mellitus

Type 2 diabetes mellitus (AE)

MPHD in adulthood, naïve

111.3

6.00

0.14

650

36.2

Mild

Not suspected

Resolved completely

Not changed

None; Cortisone acetate, statin

Type 2 diabetes mellitus (AE)

MPHD in adulthood, pretreated

94.0

NR

0.50

998

27.8

Mild

Not suspected

Ongoing

Not changed

None

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, pretreated

108.1

5.90

0.30

955

43.2

Mild

Not suspected

Ongoing

Not changed

None; Hydrocortisone, statin

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, pretreated

104.6

NR

NR

NR

NR

Mild

Not suspected

Ongoing

Not changed

None; Hydrocortisone

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, naïve

106.7

NR

0.30

9

39.2

Mild

Not suspected

Ongoing

Not changed

None; Statin

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, naïve

105.0

5.99

0.40

521

32.3

Mild

Not suspected

Ongoing

Not changed

None; Hydrocortisone, statin

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, pretreated

63.7

5.90

0.20

1274

26.1

Moderate

Not suspected

Ongoing

Not changed

None; Hydrocortisone, statin; Y

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, naïve

95.0

NR

0.36

1317

32.5

Mild

Not suspected

Ongoing

Not changed

None; Cortisone acetate, statin; Y

Type 2 diabetes mellitus (SAE)

MPHD in adulthood, naïve

100.0

6.91

0.30

260

33.8

Mild

Not suspected

Ongoing

Not changed

None; Hydrocortisone

  1. aLast documented dose before AE onset in mg/day; bTime to SAE onset after start of Omnitrope® treatment; cAssessment of relationship to study drug according to Investigator and Sponsor (worst case)
  2. AE adverse event; BMI body mass index; GHD growth hormone deficiency; HbA1c glycated hemoglobin; MedDRA Medical Dictionary for Regulatory Activities; MPHD multiple pituitary hormone deficiency; NR not recorded; PT Preferred Term; SAE serious adverse event; Y Yes